<?xml version="1.0" encoding="UTF-8"?>
<p>Antitumor activity was assessed according to the International Working Group (IWG‐2007) criteria except PET assessment for PTCL
 <xref rid="cas13513-bib-0019" ref-type="ref">19</xref> and modified Severity Weighted Assessment Tool criteria for CTCL.
 <xref rid="cas13513-bib-0010" ref-type="ref">10</xref> Assessments were carried out within 28 days prior to the start of treatment, 6 weeks after the first dose, and every 6
 <bold> </bold>weeks thereafter, or sooner if there was clinical suspicion of disease progression.
</p>
